###begin article-title 0
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 64 72 <span type="species:ncbi:9606">Patients</span>
Prevalence of BRCA1 and BRCA2 Mutations in Korean Breast Cancer Patients
###end article-title 0
###begin p 1
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 568 573 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 693 697 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1136 1140 1136 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1244 1248 1244 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 747 755 <span type="species:ncbi:9606">patients</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
###xml 863 871 <span type="species:ncbi:9606">patients</span>
###xml 1095 1103 <span type="species:ncbi:9606">patients</span>
###xml 1177 1185 <span type="species:ncbi:9606">patients</span>
###xml 1302 1310 <span type="species:ncbi:9606">patients</span>
The incidence of breast cancer in Korea has been increasing in recent years, such that it is now the most common female cancer. Breast cancer in Korea is characterized by an earlier age of onset than in Western countries, suggesting that it would be related with genetic background. We assayed germline mutations in the BRCA genes to evaluate their genetic pathology in Korean breast cancer patients. The study subjects consisted of 173 patients at clinically higher risk and 109 unselected patients. Germline mutations in the entire coding sequences of the BRCA1 and BRCA2 genes were analyzed by Conformation-Sensitive Gel Electrophoresis (CSGE), and any aberrantly-sized band was sequenced. BRCA mutations were present in 12.7% of the high risk patients, compared with 2.8% of the unselected patients. Among high risk patients, mutations were most prevalent in patients with a family history of breast or first-degree ovarian cancer (22.1%), followed by those with male breast cancer (20%), bilateral breast cancer (20%), multiple organ cancer including breast (13%) and younger breast cancer patients (aged <35 yr) (8.1%). Moreover, BRCA mutations were detected in 34.8% of patients having two high-risk factors. These findings suggest that BRCA gene mutation analysis should be performed on Korean patients with high-risk factors for breast cancer.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 620 621 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 219 224 <span type="species:ncbi:9606">women</span>
###xml 276 281 <span type="species:ncbi:9606">women</span>
The incidence of breast cancer in Korea has been increasing in recent years. Although this cancer is still much less prevalent in Korea than in Europe and the United States, it has been the most common cancer in Korean women since 2001 (1). Remarkably, the peak age of Korean women presenting with breast cancer is in the 40's, a peak age 15-20 yr younger than in the United States. One of the characteristics of hereditary breast cancer is a tendency towards younger age at onset. Breast cancer is typically diagnosed at a young age in Southeast Asia, including Korea, suggesting that genetic factors may be important (2).
###end p 3
###begin p 4
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 791 792 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 937 941 937 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 953 954 953 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 736 741 <span type="species:ncbi:9606">women</span>
Although 20% to 25% of breast cancers are familial (i.e., associated with a family history of breast cancer), in Western countries only 5% to 10% are hereditary, with an autosomal dominant genetic determinant. Most hereditary breast cancers are associated with mutations in the BRCA1 (MIN 113705) and BRCA2 (MIN 600185) genes (3), which confer high susceptibility to familial breast and/or ovarian cancer (4, 5). Ethnicity plays a role in hereditary breast cancer through its association with particular "founder" mutations. For example, founder mutations have been identified in various ethnic groups, including Icelanders, Ashkenazi Jews, Russians, and Israelis. In Iceland, a single BRCA2 mutation (BRCA2 999del5) is found in 24% of women diagnosed with breast cancer below age 40 yr (6, 7). Twelve percent of unselected Jewish breast cancer cases, including 28% of those diagnosed below age 50 yr, were found to carry 1 of 3 founder BRCA mutations (8).
###end p 4
###begin p 5
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 516 520 516 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 614 619 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
###xml 663 671 <span type="species:ncbi:9606">patients</span>
###xml 690 698 <span type="species:ncbi:9606">patients</span>
In general, there is little data on the contribution of germline BRCA mutations to breast cancer in Asia. Among unselected breast cancer cases in the Philippines, the prevalence of BRCA mutations was found to be 5.1% (2). Although nine germ-line mutations were identified in 21 Korean families, including two or more affected first- or second-degree relatives with breast and/or ovarian cancer (9), knowledge of BRCA mutations in the overall Korean breast cancer population is scanty. To determine the prevalence of BRCA germline mutations in Korean breast cancer patients, we performed mutational analysis of the BRCA1 and BRCA2 genes in high-risk breast cancer patients and in unselected patients using Conformation-Sensitive Gel Electrophoresis (CSGE).
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
Subjects
###end title 7
###begin p 8
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 1393 1397 1393 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 710 718 <span type="species:ncbi:9606">patients</span>
###xml 999 1007 <span type="species:ncbi:9606">patients</span>
###xml 1085 1093 <span type="species:ncbi:9606">patients</span>
###xml 1128 1136 <span type="species:ncbi:9606">patients</span>
The study subjects included 173 breast cancer patients at higher risk of mutating BRCA genes at Asan Medical Center, Seoul, between March 2002 and February 2003 and 109 unselected breast cancer patients treated at Korea University Guro Hospital, Seoul, between January 2000 and December 2000. The high-risk patients included 86 with familial breast or first-degree ovarian cancer histories, 74 with a younger age at onset (<35 yr), 15 bilateral cancers, 5 male breast cancers, and 16 multi-organ cancers (five thyroid cancers, three cervical cancers, three stomach cancers, one ovarian cancer, one skin cancer, and three unknown cancers), including breast cancer. Of those with familial histories, seventy-one patients had a history of breast cancer (50 in first-degree relatives including 3 with a first-degree family history of ovarian cancer, 13 in second-degree relatives, and 8 in both first and second-degree relatives including 1 with a first-degree family history of ovarian cancer). Only 7 patients had first-degree ovarian cancer histories, and the information on the rest 8 patients was not available. The unselected patients were included randomly without the information about their family histories or other high-risk factors. Subjects were asked to fill out questionnaires to evaluate their personal and family histories, and blood specimens were collected for determination of BRCA mutations. Informed consent was obtained from all the subjects in this study.
###end p 8
###begin title 9
DNA purification from EDTA-blood
###end title 9
###begin p 10
Genomic DNA was isolated from EDTA-blood using the Accuprep DNA Purification kit (Bioneer, Korea).
###end p 10
###begin title 11
Generation of polymerase chain reaction (PCR) products
###end title 11
###begin p 12
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 502 507 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 871 891 871 891 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dabb@labgenomics.com</email>
###xml 1016 1017 1008 1009 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1077 1080 1065 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
BRCA1 and BRCA2 mutations were scanned as described previously (12), with modifications. PCR products were synthesized by amplification of 75 fragments overlapping the 22 coding exons of BRCA1 and the 26 coding exons of BRCA2. PCR primers were designed to generate fragments of 220-503 bp in length covering all coding exons and at least 40 bp of each exon-intron flanking region. In order to produce 75 fragments for both genes, 31 BRCA1 fragments were generated in 9 triplexes and 2 duplexes, and 44 BRCA2 fragments were generated in 11 triplexes, 4 duplexes, and 3 singles. For generation of fluorescent PCR products, each forward primer was labeled at the 5' end with one of the phosphoramidite dyes, HEX (yellow), TET (green), or 6-FAM (blue), while the reverse primers were unlabeled. Primer sequences and multiplex PCR conditions are available on request (e-mail: dabb@labgenomics.com). Typically, PCR reactions were performed in a reaction volume of 15 microL containing 1 microL of DNA solution, 2.5 mM MgCl2, 1.25 mM dNTP, 0.5 microM of each primer and 1 U of TaKaRa Taq polymerase (TaKaRa Biomedicals, Japan). The amplification protocol consisted of denaturation at 95℃ for 10 min, followed by 35 cycles of denaturation at 95℃ for 15 sec, annealing at 57℃ for 1 min, and extension at 72℃ for 45 sec. To generate heteroduplexes, the samples were denatured at 95℃ for 5 min, annealed at 68℃ for 30 min and cooled at 4℃. A 0.3-1.0 microL aliquot of each PCR product was subsequently used for F-CSGE analysis.
###end p 12
###begin title 13
Fluorescent conformation-sensitive gel electrophoresis (F-CSGE)
###end title 13
###begin p 14
Samples were electrophoresed in 0.2 mm thick 12% polyacrylamide gels, containing a 99:1 ratio of acrylamide (BioRad, CA, U.S.A.) to 1,2 bis-(acryolyl)piperazine (Fluka, Switzerland) and 15% (v/v) formamide, in 1xTBE buffer with a 36-well comb. Samples were separated on a standard ABI 377 sequencer using 1xTBE. Each sample loading mixture contained 0.3-1.0 microL of multiplexed PCR product, 0.2 microL size standard labeled with TAMRA (GS500, Applied Biosystems, CA, U.S.A.), 0.5 microL dextran blue (50 mg/mL), and 0.5 microL freshly deionized formamide. 1-1.8 microL aliquots of the samples were applied per lane. Electrophoresis was performed at 2,000 V for 4.5 hr at 42℃ in 1xTBE, and the data were analyzed with GeneScan software (Applied Biosystems, CA, U.S.A.).
###end p 14
###begin title 15
Sequencing of PCR products
###end title 15
###begin p 16
###xml 255 261 255 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
Once a subset of PCR products with an aberrant CSGE pattern had been identified, the PCR products were re-amplified using the same primers as for CSGE and subjected to DNA sequencing in both directions on an ABI3700 genetic analyzer (Applied Biosystems) (Fig. 1).
###end p 16
###begin title 17
Interpretation of sequence analysis results
###end title 17
###begin p 18
###xml 65 91 65 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Positive for BRCA mutation</italic>
###xml 267 287 267 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Unverified mutations</italic>
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UVs</italic>
###xml 436 462 436 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Negative for BRCA mutation</italic>
The sequence analysis results were sorted into three categories. Positive for BRCA mutation included nonsense or frameshift mutations that produce prematurely terminated (truncated) protein products of BRCA1 or BRCA2, whose clinical significance has been determined. Unverified mutations (UVs) included missense mutations and mutations that occurred in analyzed intronic regions whose clinical significance has not yet been determined. Negative for BRCA mutation included samples identical to a consensus wild-type sequence as well as samples in which genetic variants of no substantial clinical consequence were identified.
###end p 18
###begin title 19
RESULTS
###end title 19
###begin p 20
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 403 409 403 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
In 109 unselected breast cancer patients, 3 individuals (2.8%) carried BRCA mutations, two in BRCA1 and one in BRCA2; of these, one was a nonsense mutation and two were frame shift mutations. In contrast, 22 of the 173 high-risk breast cancer patients (12.7%) carried BRCA mutations, 15 (8.7%) in BRCA1 and seven (4%) in BRCA2; of these, seven were nonsense mutations and 15 were frame shift mutations (Fig. 2).
###end p 20
###begin p 21
###xml 348 355 348 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
Among the 5 subsets of high risk patients, mutations were most prevalent in patients having a family history of breast or first-degree ovarian cancer (22.1%), followed by those with male breast cancer (20%), bilateral breast cancer (20%), multiple organ cancer including breast cancer (13%) and younger breast cancer patients (aged <35 yr) (8.1%) (Table 1).
###end p 21
###begin p 22
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 532 537 532 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 483 490 <span type="species:ncbi:9606">patient</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 649 657 <span type="species:ncbi:9606">patients</span>
We found that BRCA mutations were present in 8 of 23 patients (34.8%) with two high-risk factors. BRCA1 mutations were detected in 3 of 14 patients (21.4%) with family history and early-onset (<35 yr), one of 2 patients (50%) with family history and bilateral cancer, one of 2 patients (50%) with family history and male breast cancer, one of 2 patients (50%) with family history and multi-organ cancer, one of 2 patients (50%) with early-onset and bilateral cancer, and none of one patient with early-onset and multi-organ cancer. BRCA2 mutation was studied in 14 patients with family history and early-onset (<35 yr) and detected in one of the 14 patients (7.1%).
###end p 22
###begin title 23
DISCUSSION
###end title 23
###begin p 24
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 402 407 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 605 610 <span type="species:ncbi:9606">women</span>
Mutations in the BRCA1 and BRCA2 genes in females confer highly elevated risks of developing cancers of the breast and ovary. Ever since the BRCA1 and BRCA2 genes were identified in 1994 and 1995, respectively, there has been controversy over whether presymptomatic testing for these mutations would be clinically beneficial, and, if so, who would be eligible for testing (13). Since the prevalence of BRCA1 and BRCA2 mutations in most populations is low, many advisory bodies, including one under the auspices of the American Society for Clinical Oncology, have recommended that testing be restricted to women at high risk of developing breast or ovarian cancer (14).
###end p 24
###begin p 25
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
At present, hundreds of BRCA mutations are known. Most of these are nonsense or frame shift mutations, which can be found throughout the entire gene sequence and produce truncated proteins (15). Due to founder effects as well as other environmental and geographical factors, the prevalence of BRCA mutations is variable among different populations (10, 11).
###end p 25
###begin p 26
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 551 556 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 574 579 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 609 614 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 668 675 <span type="species:ncbi:9606">patient</span>
In this report, we evaluated the prevalence of BRCA1 and BRCA2 mutations in high-risk patients as well as in unselected breast cancer patients in Korea. We found that the prevalence of these mutations was about 4-5 times higher in high-risk patients than in unselected patients. To our knowledge, this is the first population-based report of BRCA mutations in breast cancer patients in Korea. Interestingly, however, we did not detect any of the three founder mutations identified in individuals of Ashkenazi Jewish decent (185delAG and 5382 insC for BRCA1 and 6174delT for BRCA2) or the 999del5 mutation for BRCA2 common to the Icelandic population (6) in any Korean patient.
###end p 26
###begin p 27
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 474 478 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 636 640 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 728 729 728 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 858 862 858 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 874 876 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 878 880 878 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 506 514 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
We found that a family history of breast or first-degree ovarian cancer was the most important high-risk factor for BRCA mutation, followed by bilateral breast cancer and male breast cancer. Each of these factors increased the likelihood of detecting BRCA mutations 7- to 8-fold compared with the unselected patients. In contrast, earlier age at onset, prior to age 35, increased the likelihood of BRCA mutations 3-fold compared with the unselected patients. Our finding of BRCA mutations in 23% of Korean patients with a family history of breast cancer is in good agreement with findings in Caucasian and other Asian patients, in whom BRCA mutations were detected in 11% to 33% of those with a family history of breast cancer (2, 19, 20, 24). In some of these studies, 45% to 51% of patients with two or more relatives with breast cancer were found to have BRCA mutations (20, 24).
###end p 27
###begin p 28
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
It has been reported that nine of 21 (43%) Korean families containing two or more affected first- or second-degree relatives with breast and/or ovarian cancer had BRCA germline mutations (four frameshift and five nonsense) (9). In our study, we detected 15 frameshift mutations and seven nonsense mutations.
###end p 28
###begin p 29
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 577 581 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
There are few reports on the prevalence of BRCA gene mutations in unselected breast cancer patients in Asia. The prevalence of these mutations has been estimated at 5.1% to 6.7%, with the phenotypes varying by ethnicity (2, 16). In our study of unselected Korean breast cancer patients, however, we detected a lower prevalence of BRCA mutations (2.8%), which may be due to ethnic differences. It should be noted, however, that the numbers of unselected Asian breast cancer patients canvassed to date is low; larger numbers may give a more accurate estimate of the frequency of BRCA mutations in Asia, as well as of the variations between Asian populations.
###end p 29
###begin p 30
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
The prevalence of BRCA mutations in patients with early-onset breast cancer is quite different depending on ethnicity. For example, this rate has been found to be 20-30% in Ashkenazi Jewish and Icelandic patients (7, 17, 18), less than 10% in Caucasian patients (19-22), and 6-11% in Asian patients, including our results (2, 23).
###end p 30
###begin p 31
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 806 810 806 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
We found that the prevalence of BRCA mutations in patients with two or more risk factors was 2.7 times higher than that in patients with a single risk factor. These risk factors included early age at diagnosis, bilateral cancer, multiple organ cancer, and male breast cancer, together with a family history of breast or first-degree ovarian cancer. For example, 28.6% of patients diagnosed prior to age 35 yr and who had a family history of breast or first-degree ovarian cancer carried BRCA mutations, a prevalence comparable to the 29.7% of non-Ashkenazi breast cancer patients diagnosed before age 40 yr who had one relative diagnosed with breast cancer before age 50 (24). In this latter report, 50.7% of these patients who had two relatives diagnosed with breast cancer before age 50 carried germline BRCA mutations (24).
###end p 31
###begin p 32
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 517 521 517 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 645 650 645 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 709 710 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 806 811 806 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
We detected BRCA mutations in 50% of patients with bilateral cancer, multiple organ cancer, or male breast cancer and a familial history, and with bilateral cancer diagnosed below age 35, although the number of patients in each category was small. Larger, population-based studies are needed to evaluate the impact of these combined risk factors on the prevalence of BRCA mutations. Interestingly, it has been reported that a family history of bilateral breast cancer did not substantially increase the likelihood of BRCA mutations (19). Previous investigations have suggested that male breast cancer may be another hallmark for the presence of BRCA2 mutations (19, 25, 26). In contrast, of the small number (5) of male breast cancer patients that we assayed, none had a BRCA2 mutation, and only one had a BRCA1 mutation.
###end p 32
###begin p 33
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 67 72 <span type="species:ncbi:9606">women</span>
###xml 237 242 <span type="species:ncbi:9606">women</span>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
###xml 564 569 <span type="species:ncbi:9606">women</span>
BRCA1 mutations have been found to be significantly more common in women with a family history of ovarian cancer than in those with a family history of breast cancer (19). In contrast, BRCA2 mutations were not found to be more common in women with a family history of ovarian cancer. In Asian countries, BRCA mutations have been detected in 4.7% to 15.8% of patients with ovarian cancer (16, 27). While the prevalence of BRCA mutations has been shown to be increased in patients with earlier onset breast cancer, the prevalence of these mutations was no higher in women with ovarian cancer diagnosed before age 50 than in those diagnosed at a later age (24).
###end p 33
###begin p 34
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
We believe that our data on the personal and family histories of the individuals tested are accurate because the information was obtained from the test requisition form by a research fellow. Moreover, the F-CSGE technique we used has been found to detect 98% of BRCA mutations, a sensitivity at least equal to that of other gel-based genomic screening techniques (28).
###end p 34
###begin p 35
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 435 439 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 729 733 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 768 776 <span type="species:ncbi:9606">patients</span>
Generally, tests for BRCA mutations are recommended in cases with 10% or higher prevalence rate of the mutation in a clinical setting. Our study data suggest that breast cancer patients with high-risk factors, including a family history of breast or first-degree ovarian cancer, bilateral cancer, male breast cancer, multiple organ cancer, and earlier age at onset, who have a higher prevalence of BRCA mutations, should be tested for BRCA mutations. Our finding, that the phenotype of BRCA mutations in Korea is different from those of Ashkenazi Jew and other populations, suggests the need for large-scale, population-based studies to establish the clinicopathologic characteristics as well as the genetic pathology related to BRCA mutations in Korean breast cancer patients.
###end p 35
###begin p 36
This work was supported by the Korea Research Foundation Grant (KRF-2001-042-F00063).
###end p 36
###begin article-title 37
###xml 46 54 <span type="species:ncbi:9606">patients</span>
BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines
###end article-title 37
###begin article-title 38
Hereditary breast cancer
###end article-title 38
###begin article-title 39
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
###end article-title 39
###begin article-title 40
Identification of the breast cancer susceptibility gene BRCA2
###end article-title 40
###begin article-title 41
###xml 79 87 <span type="species:ncbi:9606">patients</span>
High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients
###end article-title 41
###begin article-title 42
Population-based study of risk of breast cancer in carriers of BRCA2 mutation
###end article-title 42
###begin article-title 43
###xml 91 96 <span type="species:ncbi:9606">women</span>
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer
###end article-title 43
###begin article-title 44
Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families
###end article-title 44
###begin article-title 45
Ethnic differences in cancer risk resulting from genetic variation
###end article-title 45
###begin article-title 46
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer
###end article-title 46
###begin article-title 47
Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure
###end article-title 47
###begin article-title 48
BRCA1-lots of mutations, lots of dilemmas
###end article-title 48
###begin article-title 49
BRCA1 and BRCA2 testing: weighing the demand against the benefits
###end article-title 49
###begin article-title 50
Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan
###end article-title 50
###begin article-title 51
###xml 62 67 <span type="species:ncbi:9606">women</span>
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer
###end article-title 51
###begin article-title 52
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 183 188 <span type="species:ncbi:9606">women</span>
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 percent of ovarian cancer and 30 percent of early-onset breast cancer patients among Ashkenazi women
###end article-title 52
###begin article-title 53
Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases
###end article-title 53
###begin article-title 54
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
###end article-title 54
###begin article-title 55
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer
###end article-title 55
###begin article-title 56
###xml 89 94 <span type="species:ncbi:9606">women</span>
BRCA1 mutations and other sequence variations in a population-based sample of Australian women with breast cancer
###end article-title 56
###begin article-title 57
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients
###end article-title 57
###begin article-title 58
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals
###end article-title 58
###begin article-title 59
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population
###end article-title 59
###begin article-title 60
###xml 19 24 <span type="species:ncbi:9606">women</span>
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
###end article-title 60
###begin article-title 61
Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population
###end article-title 61
###begin article-title 62
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
###end article-title 62
###begin p 63
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 93 94 93 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 127 128 127 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 178 182 178 182 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A, C</bold>
A typical scan of a F-CSGE fragment which harbors the BRCA1 sequence variations T875C (panel B) and 1041_1043delAGCinsT (panel D) in comparison with the wild-type control (panel A, C).
###end p 63
###begin p 64
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
BRCA mutations in breast cancer patients with high-risk factors in Korea (n=173). *UV, unverified mutation.
###end p 64
###begin p 65
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
BRCA mutations in high-risk patients with breast cancer in Korea
###end p 65
###begin p 66
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*Of total 173 cases, 23 cases have two high-risk factors.
###end p 66

